Evogene (TSE:EVGN – Free Report) had its target price cut by Desjardins from C$3.00 to C$2.00 in a research report report published on Wednesday morning,BayStreet.CA reports. They currently have a buy rating on the stock.
Separately, Royal Bank of Canada set a C$1.00 price objective on Evogene and gave the company a “sector perform” rating in a research note on Wednesday.
Get Our Latest Report on Evogene
Evogene Stock Performance
Evogene Company Profile
Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements.
Further Reading
- Five stocks we like better than Evogene
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Intuit’s AI Boom: Stock Soaring, But Should Investors Hit Pause?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Top Dividend Plays With Strong Analyst Ratings
- 3 Monster Growth Stocks to Buy Now
- Robinhood Stock Keeps Giving Investors Reasons To Buy
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
